Landscape Capital Management L.L.C. Makes New Investment in Zoetis Inc. $ZTS

Landscape Capital Management L.L.C. bought a new stake in Zoetis Inc. (NYSE:ZTS – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,977 shares of the company’s stock, valued at approximately $487,000.

Other large investors have also made changes to their positions in the company. Composition Wealth LLC boosted its holdings in shares of Zoetis by 23.6% in the third quarter. Composition Wealth LLC now owns 3,638 shares of the company’s stock worth $254,000 after buying an additional 694 shares during the last quarter. Muhlenkamp & Co. Inc. purchased a new stake in Zoetis during the third quarter valued at approximately $7,977,000. Stelac Advisory Services LLC purchased a new stake in Zoetis during the third quarter valued at approximately $1,275,000. Clark Estates Inc. NY bought a new stake in Zoetis during the 3rd quarter worth approximately $2,489,000. Finally, South Dakota Investment Council raised its position in shares of Zoetis by 5.8% during the 3rd quarter. South Dakota Investment Council now owns 624,249 shares of the company’s stock valued at $43,591,000 after purchasing an additional 34,147 shares during the period. Institutional investors own 92.80% of the company’s stock.

Recent Zoetis Headlines

These are some of the ZTS headlines that stood out recently:

Analyst Ratings Changes

Several research analysts recently weighed in on ZTS shares. Morgan Stanley dropped their target price on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a report on Thursday, October 29th. Cantor Fitzgerald set a $94.00 price target on Zoetis in a report on Tuesday, August 25th. Piper Sandler decreased their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. TD Cowen lowered their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. Finally, BTIG Research dropped coverage on Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $101.25.

View Our Latest Stock Report on ZTS

Zoetis Price Performance

NYSE:ZTS opened at $79.09 on Friday. The firm has a market capitalization of $32.14 billion, a price-to-earnings ratio of 13.45, a PEG ratio of 1.22 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.35 and a quick ratio of 1.40. The business has a 50 day simple moving average of $77.16 and a 200-day simple moving average of $90.55. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49.

Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the business posted $1.70 earnings per share. The business’s revenue was down 1.3% compared to the same quarter last year. Equities analysts forecast that Zoetis Inc. will post 6.29 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is presently 36.05%.

Zoetis Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.